Novavax, Inc. (NASDAQ: NVAX) is a stock that I’ve kept a close eye on for some time, and for good reason. When I first came across the company about a year and a half ago, I dug into the pipeline and quickly became impressed. Since then, the company has evolved a bit, and in my opinion, has become a perfect buyout candidate. Today, we’ll talk about:
- What NVAX does;
- Why the company’s pipeline is so impressive;
- Why I believe that the stock is a perfect takeover candidate;
- The value proposition even without a takeover; and
- What you should be watching for ahead.
What Does NVAX Do?
Novavax, as their name somewhat suggests, is a company that is focused on the development of vaccines. The company invented a recombinant nanoparticle vaccine technology, and through this proprietary technology, it produces vaccine candidates surrounding both known and emerging disease threats. All of the vaccines in the company’s pipeline were engineered by NVAX as three-dimensional nanostructures that incorporate recombinant proteins that are critical to disease pathogenesis. Through this unique take on vaccinations, the company has created several promising candidates and seems to be inching closer and closer to FDA approval.
What’s So Impressive About The Pipeline?
In my opinion, there are a few things that are impressive about the company’s pipeline. First and foremost, the sheer number of clinical programs in development at the moment. The company is currently working on an RSV vaccine that’s targeted for older adults, infants, and pediatrics. On top of that, Ebola and Zika virus vaccines are in the works. On a pre-clinical level, the company is working on a vaccine for a combination of respiratory issues.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
However, the most impressive product in the NVAX pipeline, at least in my opinion, is NanoFlu. This is the company’s nanoparticle influenza vaccine, more commonly known as the flu vaccine. While there are several flu vaccine options on the market today, this one is particularly special. Ultimately, flu vaccines are proving to be less and less effective each year, but the unique way in which NanoFlu goes about protecting its host from the flu could make it the leader in the industry.